Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIOD-105
- Development stage
- Phase 1
- Administration
- Subcutaneous
01
Overview
BIOD-105 is a pipeline drug, referenced in pharmaceutical development sources, but explicit public details regarding its mechanism of action, molecular target, modality, developer, or clinical phase are unavailable as of September 2025. No direct clinical candidate description, structural classification, or trial data for this candidate is provided in public databases or scientific literature. Some confusion may arise from similar code numbers (e.g., BIO-105, MB-105), but these reference distinct agents unrelated in mechanism or developer to BIOD-105.
- Brand names
- BIOD-105BIOD105BIOD 105
- Other names
- BIOD-105BIOD105BIOD 105
02
Targets
CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on BIOD-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIOD-105.